Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Halank

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Onkologie|December 9, 2004
Severe pulmonary hypertension in chronic idiopathic myelofibrosisM Halank, C Marx, G Baretton, et al.
Deutsche Medizinische Wochenschrift (1946)|August 7, 1998
[Precapillary pulmonary hypertension of uncertain etiology]M Halank, M Wiemer, C Tschöpe, et al.
Deutsche Medizinische Wochenschrift (1946)|March 25, 2011
[Hemoptysis because of pulmonary vein stenosis and occlusion after pulmonary vein isolation for atrial fibrillation]S Braun, M Kolditz, M Halank, et al.
Chest|November 20, 2001
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertensionC Rubens, R Ewert, M Halank, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|June 3, 2008
L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertensionJ Beyer, M Kolditz, R Ewert, et al.
The European Respiratory Journal|March 2, 2005
Bosentan therapy for portopulmonary hypertensionM M Hoeper, M Halank, C Marx, et al.
Zeitschrift Fur Gastroenterologie|September 3, 2011
Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertensionM Halank, L Knudsen, H-J Seyfarth, et al.
The European Respiratory Journal|July 27, 2007
Experience with inhaled iloprost and bosentan in portopulmonary hypertensionM M Hoeper, H J Seyfarth, G Hoeffken, et al.
Pneumologie (Stuttgart, Germany)|October 14, 2005
[A role for combination therapy in pulmonary arterial hypertension]J Behr, M M Borst, J Winkler, et al.
The European Respiratory Journal|June 10, 2010
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II studyH A Ghofrani, M M Hoeper, M Halank, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Onkologie|December 9, 2004
Severe pulmonary hypertension in chronic idiopathic myelofibrosisM Halank, C Marx, G Baretton, et al.
Deutsche Medizinische Wochenschrift (1946)|August 7, 1998
[Precapillary pulmonary hypertension of uncertain etiology]M Halank, M Wiemer, C Tschöpe, et al.
Deutsche Medizinische Wochenschrift (1946)|March 25, 2011
[Hemoptysis because of pulmonary vein stenosis and occlusion after pulmonary vein isolation for atrial fibrillation]S Braun, M Kolditz, M Halank, et al.
Chest|November 20, 2001
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertensionC Rubens, R Ewert, M Halank, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|June 3, 2008
L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertensionJ Beyer, M Kolditz, R Ewert, et al.
The European Respiratory Journal|March 2, 2005
Bosentan therapy for portopulmonary hypertensionM M Hoeper, M Halank, C Marx, et al.
Zeitschrift Fur Gastroenterologie|September 3, 2011
Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertensionM Halank, L Knudsen, H-J Seyfarth, et al.
The European Respiratory Journal|July 27, 2007
Experience with inhaled iloprost and bosentan in portopulmonary hypertensionM M Hoeper, H J Seyfarth, G Hoeffken, et al.
Pneumologie (Stuttgart, Germany)|October 14, 2005
[A role for combination therapy in pulmonary arterial hypertension]J Behr, M M Borst, J Winkler, et al.
The European Respiratory Journal|June 10, 2010
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II studyH A Ghofrani, M M Hoeper, M Halank, et al.
Pageof 6